TIGIT and cancer: Similar to the CD28/CTLA-4 pathway, CD96 and TIGIT act as co-inhibitory receptors together with the co-stimulatory receptor CD226, which supports the contention that CD96 and TIGIT could be targeted for cancer immunotherapy11.